Mindray Medical reported much improved results for its second quarter, the first quarter that included its acquisition of Datascope’s patient monitoring business. The acquisition was completed on May 1, so Mindray’s Q2 report reflects two months of combined operation. In Q2, revenues climbed 100% to $145.7 million and net income was up an even greater 139% at $36.7 million. More details...
Stock Symbol: (NYSE: MR)